Dihexa Research Guide: Angiotensin IV Analog, HGF/c-Met Mechanism, Synaptogenesis Literature, and Verification

Most small peptides borrowed from endogenous signaling systems are weak, short-lived, and easily degraded — which is exactly why the angiotensin IV field spent two decades engineering around those limitations. Dihexa is the endpoint of that effort: a heavily modified, metabolically stabilized analog of angiotensin IV designed to survive in solution, cross the blood-brain barrier, and act at a growth-factor system rather than a classical peptidase target. For a research library focused on the neurobiology of synapse formation, it is one of the more mechanistically interesting probe compounds available, because its activity converges on a single, well-mapped receptor system: the hepatocyte growth factor (HGF) and its receptor, c-Met. This guide surveys dihexa at the molecular and preclinical level — what it is, how it was built, the pathway it engages, what the primary literature actually reports, and how a research group should evaluate the material it sources.

The information below is provided for in-vitro and preclinical laboratory research context only. Nothing here describes human use, dosing, or therapeutic outcomes.

Section 1 — Molecular Profile

Dihexa (development code PNB-0408, and sometimes written as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide) is not a naturally occurring sequence. It is a synthetic construct derived from angiotensin IV — specifically from the Nle¹-angiotensin IV template — through a deliberate program of chemical stabilization. The design retains the core Tyr-Ile pharmacophore that angiotensin IV analogs depend on, caps the N-terminus with a hexanoyl (six-carbon acyl) group in place of the original N-terminal residue, and replaces the C-terminal His-Pro-Phe tail with a 6-aminohexanoic amide moiety. Those two modifications are the whole point of the molecule: they shield the peptide from the aminopeptidases and carboxypeptidases that dismantle native angiotensin IV within minutes, producing a compound stable enough to study and lipophilic enough to be reported as orally active and brain-penetrant in preclinical models.

Dihexa (PNB-0408)
– CAS number: 1401708-83-5
– Molecular formula: C₂₇H₄₄N₄O₅
– Molecular weight: approximately 504.66 g/mol (504.7 Da)
– Chemical class: metabolically stabilized angiotensin IV (AngIV) analog
– Parent template: Nle¹-angiotensin IV
– Key structural features: N-terminal hexanoyl cap; retained Tyr-Ile core; C-terminal 6-aminohexanoic amide
– Physical form: lyophilized powder

Two details matter for anyone characterizing this molecule analytically. First, dihexa is a small, capped, non-natural peptide-like compound rather than a standard amino-acid chain, so identity confirmation rests on matching the exact target mass of roughly 504.7 Da and the expected fragmentation pattern, not on simple sequence assumptions. Second, the acyl cap and the aminohexanoic tail give the compound markedly greater lipophilicity than a typical hydrophilic research peptide, which affects solubility handling and reversed-phase separation behavior. These are the practical fingerprints a laboratory should confirm rather than infer.

Section 2 — Mechanism

Dihexa’s mechanism is best described strictly at the receptor and pathway level, and here the compound is unusually well defined. Its proposed molecular action is not on the angiotensin receptors one might assume from its lineage, but on the hepatocyte growth factor (HGF) / c-Met system. In binding studies, dihexa has been reported to associate with HGF at high affinity (a dissociation constant in the picomolar range, Kd ≈ 65 pM) and to potentiate HGF-dependent activation of the c-Met receptor tyrosine kinase.

The relevant model is one of augmentation rather than direct agonism. HGF is a growth factor that normally exists as an inactive monomer and must dimerize to activate c-Met. The published interpretation is that dihexa stabilizes or facilitates HGF dimerization, so that at subthreshold concentrations of HGF — levels that would not otherwise trigger the receptor — c-Met phosphorylation nonetheless proceeds. In other words, dihexa is studied as a positive modulator of an existing growth-factor signal, not as a ligand that switches the receptor on by itself.

Downstream of c-Met activation, the pathways engaged are the canonical receptor-tyrosine-kinase cascades. Phosphorylated c-Met recruits adaptor proteins that activate the PI3K/AKT axis and the Ras/MAPK (ERK) cascade. In the neuronal model systems where dihexa has been characterized, these signaling events are associated with dendritic spine formation (spinogenesis) and the assembly of new functional synapses (synaptogenesis) in hippocampal cultures. The literature frames this as the molecular basis for the compound’s classification as a “procognitive” or synaptogenic research agent — meaning the readouts measured are spine density, synaptic markers, and pathway phosphorylation in defined cell and tissue systems, not clinical endpoints.

Everything above is framed at the level the research merits: high-affinity binding, growth-factor dimerization, receptor-kinase phosphorylation, and downstream PI3K/AKT and MAPK activation measured in defined in-vitro and preclinical systems.

Section 3 — Preclinical Research Data

The HGF/c-Met system that dihexa engages is among the better-characterized growth-factor pathways in developmental and neuronal biology, and dihexa itself emerged from a systematic medicinal-chemistry effort to convert a fragile endogenous peptide into a stable experimental tool. The foundational work established that C-terminally truncated Nle¹-angiotensin IV analogs facilitate hippocampal synaptogenesis and correlate with spatial-memory performance in rodent model systems — the observation that launched the entire program.

Subsequent studies traced the mechanism to its source. In cultured hippocampal neurons, dihexa and its parent Nle¹-AngIV were shown to induce c-Met phosphorylation in the presence of subthreshold HGF concentrations, and to drive spinogenesis and synaptogenesis in a manner that could be blocked by disrupting the HGF/c-Met interaction — the key experiment demonstrating that the synaptogenic effect is dependent on that specific system rather than on an angiotensin-receptor route. Reported potency in these neurotrophic assays was strikingly high; in one comparison the compound’s synaptogenic activity was described as several orders of magnitude greater than that of brain-derived neurotrophic factor (BDNF) on a molar basis, a figure that reflects an in-vitro assay comparison and not a clinical claim.

Additional preclinical reports have examined dihexa in transgenic rodent models of amyloid pathology (for example, the APP/PS1 mouse), where investigators studied cognitive-task performance alongside markers of the PI3K/AKT signaling pathway. Across these datasets, the consistent through-line is convergence on a single mechanism: whatever the model system, the measured effects track with HGF/c-Met engagement and its downstream kinase cascades. That mechanistic specificity — a defined modulator acting on a defined receptor system, with effects abolished when that system is blocked — is what makes dihexa a useful and reproducible experimental probe for the biology of synapse formation.

Section 4 — Published Literature

The following are real, published, peer-reviewed references useful for a dihexa research library:

• Benoist CC, Wright JW, Zhu M, Appleyard SM, Wayman GA, Harding JW. “Facilitation of hippocampal synaptogenesis and spatial memory by C-terminal truncated Nle1-angiotensin IV analogs.” Journal of Pharmacology and Experimental Therapeutics, 2011;339(1):35-44.
• Kawas LH, McCoy AT, Yamamoto BJ, Wright JW, Harding JW. “Development of angiotensin IV analogs as hepatocyte growth factor/Met modifiers.” Journal of Pharmacology and Experimental Therapeutics, 2012;340(3):539-548.
• McCoy AT, Benoist CC, Wright JW, Kawas LH, Bule-Ghogare JM, Zhu M, Appleyard SM, Wayman GA, Harding JW. “Evaluation of metabolically stabilized angiotensin IV analogs as procognitive/antidementia agents.” Journal of Pharmacology and Experimental Therapeutics, 2013;344(1):141-154 (PMID 23055539).
• Benoist CC, Kawas LH, Zhu M, Tyson KA, Stillmaker L, Appleyard SM, Wright JW, Wayman GA, Harding JW. “The procognitive and synaptogenic effects of angiotensin IV-derived peptides are dependent on activation of the hepatocyte growth factor/c-Met system.” Journal of Pharmacology and Experimental Therapeutics, 2014;351(2):390-402.
• Wright JW, Harding JW. “The Brain Hepatocyte Growth Factor/c-Met Receptor System: A New Target for the Treatment of Alzheimer’s Disease.” Journal of Alzheimer’s Disease, 2015;45(4):985-1000.
• Chen X, et al. “AngIV-Analog Dihexa Rescues Cognitive Impairment and Recovers Memory in the APP/PS1 Mouse via the PI3K/AKT Signaling Pathway.” Brain Sciences, 2021;11(11):1487.

These references trace dihexa from the medicinal chemistry that produced it, through the binding and cell-culture work that mapped its HGF/c-Met mechanism, to the transgenic-model studies that examined its downstream signaling — the primary literature a research group needs to design and interpret in-vitro work.

Section 5 — Research Applications (In-Vitro)

Within a laboratory research context, dihexa is studied for a set of overlapping, model-system purposes:

• HGF/c-Met modulator reference compound: as a defined positive modulator for probing HGF-dependent c-Met phosphorylation in receptor-tyrosine-kinase reporter and Western-blot assays, including subthreshold-HGF augmentation designs.
• Synaptogenesis and spinogenesis models: characterizing dendritic spine density, synaptic-marker expression, and neurite outcomes in cultured hippocampal or cortical neurons exposed to the compound in vitro.
• PI3K/AKT and MAPK pathway studies: using dihexa as a tool to activate and dissect the downstream kinase cascades associated with c-Met signaling in neuronal cell systems.
• Comparative neurotrophic assays: benchmarking synaptogenic potency against reference growth factors such as HGF and BDNF on a molar basis in controlled culture conditions.
• Analytical method development: the lipophilic, capped structure and ~504.7 Da target mass make dihexa a useful test article for validating reversed-phase HPLC separations and LC-MS identity confirmation of a small non-natural peptide-like compound.

Every one of these applications is an in-vitro or model-system use. None involves administration to humans or animals for outcome measurement.

Section 6 — How to Evaluate a Source

Because research-grade dihexa is supplied as a research chemical rather than a finished preparation, documentation is the only meaningful quality signal. When comparing suppliers, researchers should look for:

• A lot-specific Certificate of Analysis (COA) that names the exact batch it describes, not a generic marketing spec sheet.
• HPLC purity data with a visible chromatogram rather than a bare percentage — important for a small capped compound where incomplete acylation or truncated intermediates are realistic synthesis byproducts.
• LC-MS or MS identity confirmation of the ~504.7 Da target mass and expected fragmentation, since the non-natural cap and tail cannot be inferred from a sequence label alone.
• Endotoxin and heavy-metal testing for lyophilized material intended for cell-based neuroscience work, where contaminants can confound sensitive signaling readouts.
• An independent, accredited testing laboratory named on the COA and verifiable at that lab’s own domain, rather than a screenshot hosted by the vendor.

As a market-context note, research-grade dihexa is widely listed, typically in small vials — 5 mg and 10 mg formats advertised across a broad price range, with entry listings starting near $40 and larger or better-documented lots running higher. That spread tells you nothing about identity on its own. For a compound this lipophilic and this potent in culture, the questions that matter are whether the material is what the label claims and whether it is clean enough for a sensitive assay — questions only third-party analytical data can answer. An undocumented low-price vial is a risk, not a bargain.

Section 7 — The PYXAX Verification Standard

PYXAX uses accredited independent laboratories in its verification network, including ILS Labs, Krause Analytical, and Janoshik. The current per-batch panel covers purity by HPLC, potency against label claim, and identity by LC-MS. A lot-specific COA is published in the COA Library before dispatch and names the laboratory that tested that batch. Endotoxin, heavy-metals, and final-vial sterility screening are not part of the current panel.

For a compound like dihexa, this verification is not a formality. Identity confirmation is decisive: because the molecule is a non-natural, capped analog rather than a recognizable amino-acid sequence, only orthogonal MS identity against the ~504.7 Da target distinguishes authentic material from a mislabeled or partially synthesized substitute. Purity by chromatogram matters just as much for a small capped compound where synthesis intermediates are plausible impurities, and endotoxin control is essential for any material destined for neuronal cell culture, where contamination can distort the very signaling readouts under study. PYXAX publishes available lot-specific analytical files in the COA Library rather than substituting a generic spec sheet. Explore the current verification documents in the COA library at /coa-library/, review the PYXAX analytical standard at /standard/, and see available research compounds at /shop/. Product-specific data is linked from each listing at /product/dihexa/.

All PYXAX compounds are supplied strictly for in-vitro and preclinical laboratory research use only. Not for human consumption. Not for veterinary use. Not for diagnostic procedures. These statements have not been evaluated by the FDA. Researchers are responsible for compliance with all applicable laws and regulations governing the use of research compounds in their jurisdiction.